These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35027426)

  • 1. Large-scale manufacturing and characterization of CMV-CD19CAR T cells.
    Wang X; Urak R; Walter M; Guan M; Han T; Vyas V; Chien SH; Gittins B; Clark MC; Mokhtari S; Cardoso A; Diamond DJ; Zaia J; Forman SJ; Nakamura R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35027426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.
    Wang X; Wong CW; Urak R; Mardiros A; Budde LE; Chang WC; Thomas SH; Brown CE; La Rosa C; Diamond DJ; Jensen MC; Nakamura R; Zaia JA; Forman SJ
    Clin Cancer Res; 2015 Jul; 21(13):2993-3002. PubMed ID: 25838392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
    Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
    J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine.
    Wang X; Diamond DJ; Forman SJ; Nakamura R
    Int J Hematol; 2021 Nov; 114(5):544-553. PubMed ID: 34561840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
    Mock U; Nickolay L; Philip B; Cheung GW; Zhan H; Johnston ICD; Kaiser AD; Peggs K; Pule M; Thrasher AJ; Qasim W
    Cytotherapy; 2016 Aug; 18(8):1002-1011. PubMed ID: 27378344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
    Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
    J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
    Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
    Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
    Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
    Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies.
    Zhao Y; Liu Z; Wang X; Wu H; Zhang J; Yang J; Zhang F; Liu L; Long J; Lu P; Chen Z
    Clin Cancer Res; 2019 Sep; 25(18):5595-5607. PubMed ID: 31300451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.
    Beloki L; Ramírez N; Olavarría E; Samuel ER; Lowdell MW
    Cytotherapy; 2014 Oct; 16(10):1390-408. PubMed ID: 24954783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.
    Michels KR; Sheih A; Hernandez SA; Brandes AH; Parrilla D; Irwin B; Perez AM; Ting HA; Nicolai CJ; Gervascio T; Shin S; Pankau MD; Muhonen M; Freeman J; Gould S; Getto R; Larson RP; Ryu BY; Scharenberg AM; Sullivan AM; Green S
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
    Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
    J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.
    Malakhova E; Pershin D; Kulakovskaya E; Vedmedskaia V; Fadeeva M; Lodoeva O; Sozonova T; Muzalevskii Y; Kazachenok A; Belchikov V; Shelikhova L; Molostova O; Volkov D; Maschan M
    Cytotherapy; 2024 Jun; 26(6):567-578. PubMed ID: 38493403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful isolation and expansion of CMV-reactive T cells from G-CSF mobilized donors that retain a strong cytotoxic effector function.
    Samuel ER; Newton K; Mackinnon S; Lowdell MW
    Br J Haematol; 2013 Jan; 160(1):87-100. PubMed ID: 23043413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T.
    Ruggeri Barbaro N; Drashansky T; Tess K; Djedaini M; Hariri R; He S; van der Touw W; Karasiewicz K
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38684370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.
    Stroncek DF; Ren J; Lee DW; Tran M; Frodigh SE; Sabatino M; Khuu H; Merchant MS; Mackall CL
    Cytotherapy; 2016 Jul; 18(7):893-901. PubMed ID: 27210719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
    Hobeika A; Osada T; Serra D; Peplinski S; Hanson K; Tanaka Y; Niedzwiecki D; Chao N; Rizzieri D; Lyerly H; Clay T; Morse M
    Cytotherapy; 2008; 10(3):289-302. PubMed ID: 18418774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.